Hypercalcemia
Drug research and approvals for hypercalcemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 19, 2026, 8 studies of hypercalcemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, FDA has 7 approved and 1 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 8
- Trials authorized in Canada: 1
- FDA orphan approvals: 7
- EU medicines: 3
- The GranStone TrialNCT07828002 · Phase 2 / Phase 3 · Martin Blomberg Jensen · starts Oct 20, 2026
- Evaluation of the Role of Luteinizing Hormone (LH) and Human Chorionic Gonadotropin (hCG) in Adult Patients Undergoing…NCT07824102 · Not reported · Martin Blomberg Jensen · starts Jan 1, 2026
- Registry for Hypoparathyroidism WuerzburgNCT05585593 · Not reported · University of Wuerzburg · starts Oct 18, 2017
- Vitamin D Analog in Vitamin D 24-hydroxylase DeficiencyNCT04987073 · Not applicable · University Hospital, Caen · starts Jul 17, 2022
- Hypercalcemia After Paraffin Oil InjectionNCT04292288 · Not reported · Martin Blomberg Jensen · starts Apr 1, 2019
- Exploring Pathogenesis and Treatment of Hypercalcemia Caused by Intramuscular Injection of ParaffinoilNCT04265599 · Not reported · Herlev Hospital · starts Apr 30, 2019
- Calcitonin Pre-treatment to Improve SPECT-CT SensitivityNCT03935984 · Phase 4 · Joseph Sferra · starts May 29, 2019
- Rifampin in CYP24A1-related Hypercalcemia and HypercalciuriaNCT03301038 · Phase 2 · Children's Hospital of Philadelphia · starts Jul 25, 2018
Approved 8
- DenosumabTumor necrosis factor ligand superfamily member 11 inhibitor
- Calcitonin salmonCalcitonin receptor agonist
- CinacalcetCalcium sensing receptor positive allosteric modulator
- PrednisoneGlucocorticoid receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- Zoledronic acidFarnesyl diphosphate synthase inhibitor
- Ibandronic acidFarnesyl diphosphate synthase inhibitor
Phase 1 or earlier 1
- RifampinBacterial DNA-directed RNA polymerase inhibitor
How its trials ended
47 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 12 whose ending is known, 33% met their primary endpoint, 0% missed it and 67% stopped early.
- Completed, result not reported1838%
- Status unknown919%
- Ongoing817%
- Stopped: other or unclear511%
- Met its primary endpoint49%
- Stopped: enrollment or feasibility24%
- Stopped: funding12%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Sep 26, 2017 | Rifampin to reduce elevated levels of blood and urine calcium in patients with idiopathic infantile hypercalcemiaRifampin | The Hospital for Sick Children | Closed |
| Dec 5, 2014 | XgevaTo treat hypercalcemia of malignancy refractory to biphosphonate therapy. | Amgen, Inc. | Approved |
| Nov 21, 2014 | SensiparTreatment of hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of… | Amgen, Inc. | Approved |
| Feb 25, 2011 | SensiparTreatment of severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy | Amgen, Inc. | Approved |
| Mar 8, 2004 | SensiparTreatment of hypercalcemia in patients with parathyroid carcinoma | Amgen, Inc. | Approved |
| Aug 20, 2001 | Zometa, ZabelTreatment of hypercalcemia of malignancy. | Novartis Pharmaceuticals Corp. | Approved |
| Jan 17, 1991 | GaniteTreatment of hypercalcemia of malignancy. | Solopak Pharmaceutical Co. | Approved |
| Apr 21, 1987 | DidronelTreatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration. | MGI Pharma, Inc. | Approved |
| Jun 16, 1993 | Disodium clodronateTreatment of hypercalcemia of malignancy. | Discovery Experimental & Development, Inc. | Designated |
| Jan 16, 2014 | Zoledronic Acid AccordZoledronic acid · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Jan 21, 2011 | IasibonIbandronic acid · generic | Pharmathen S.A. | EMA ↗ |
| Jun 25, 1996 | BondronatIbandronic acid | Atnahs Pharma Netherlands B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA